title: Long-term success of combined kidney-lung transplantation in a patient with cystic fibrosis.
abstract: Advanced kidney disease is usually considered an absolute contraindication for lung transplantation due to the difficult management of these patients in the post-operative period. Combined lung-kidney transplantation, however, could offer an opportunity for selected patients with renal and pulmonary dysfunction. This study summarizes the long-term success of a double transplantation in a 38-year-old male patient with cystic fibrosis who presented respiratory and kidney failure. After a complicated post-operative period, the patient currently lives completely independently 46 months after the operation and he enjoys excellent pulmonary and renal function.
authors: Servicio de Cirugía Torácica y Trasplante Pulmonar, Hospital Universitario de A Coruña, A Coruña, Spain. jbormat@sergas.es
authors: José M
authors: JM
authors: Borro
authors: Pablo
authors: P
authors: Rama
authors: Teresa
authors: T
authors: Rey
authors: Constantino
authors: C
authors: Fernández-Rivera
mesh_terms: D000208:Acute Disease; D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000077552:Basiliximab; D060085:Coinfection; D003550:Cystic Fibrosis / Q000150:complications*; D006084:Graft Rejection / Q000209:etiology / Q000628:therapy; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007676:Kidney Failure, Chronic / Q000209:etiology / Q000601:surgery* / Q000628:therapy; D016030:Kidney Transplantation; D016040:Lung Transplantation; D008297:Male; D009173:Mycophenolic Acid / Q000031:analogs & derivatives / Q000627:therapeutic use; D011014:Pneumonia / Q000150:complications; D011241:Prednisone / Q000627:therapeutic use; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use; D020127:Recovery of Function; D006435:Renal Dialysis; D012131:Respiratory Insufficiency / Q000209:etiology / Q000382:microbiology / Q000601:surgery*; D016559:Tacrolimus / Q000627:therapeutic use
chemical_list: D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents; D011993:Recombinant Fusion Proteins; D000077552:Basiliximab; D009173:Mycophenolic Acid; D011241:Prednisone; D016559:Tacrolimus